Alessandro Scoppola
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alessandro Scoppola has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
- Roberto Attanasio
Scientific Committee Associazione Medici Endocrinologi Milan Italy
4 shared publications Agostino Paoletta
Endocrinology, ULSS6 Euganea, Padua, Italy
3 shared publications- Ilaria Valentini
Graduate School of Health Economics and Management (ALTEMS), Catholic University of the Sacred Heart, Rome, Italy
3 shared publications Irene Samperi
Endocrinology, ASL Novara, Novara, Italy
3 shared publications- Michele Basile
Altems Advisory, spin-off dell’Università Cattolica del Sacro Cuore, Roma - Italy
3 shared publications - Roberto Novizio
Catholic University of the Sacred Heart, Rome, Italy
3 shared publications
Latest Publications
- Open Access
- 23 July 2025
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 48 (10) , 2295-2313
Italian guidelines for the management of adult individuals with primary hypothyroidism outside pregnancy
Aim: The present guideline (GL) is aimed to improve and standardize the treatment of primary hypothyroidism in non-pregnant adults and to offer all the patients the best possible care across the Italian country. Target population: Non-pregnant adults with hypothyroidism. Excluded population: This GL does not cover the treatment of hypothyroidism in children and adolescents under 18 years of age, in women who are pregnant or breastfeeding, nor in subjects with central hypothyroidism. Also patients who require suppressive therapy with levothyroxine after thyroidectomy for thyroid cancer and those with transient iatrogenic hypothyroidism were not considered in this GL. Methods: The direct costs and the utilization of resources over time were evaluated for the implementation of the appropriate management within the National Health Service. Recommendations were based on the analysis, according to the GRADE methodology, of the evidence from literature. Patients preferences were collected and verified by means of specific bibliographic research and the active participation of two patients’ representatives in the GL development group. Results: The present GL provides 4 formal graded recommendations and 16 ungraded indications for good clinical practice. An elevated agreement was consistently obtained among the panel members. Conclusions: The present GL provides operative recommendations—based on the best available evidence and cost-effectiveness analysis—for the treatment of adult patients with primary hypothyroidism. The expected benefits from the dissemination, application and implementation of this GL are the improvement of the quality of care, its homogenization across the national territory and the rationalization of health expenditure in the respect of patient preferences.
- 23 July 2025
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 48 (10) , 2295-2313
Open AccessItalian guidelines for the management of adult individuals with primary hypothyroidism outside pregnancy
Aim: The present guideline (GL) is aimed to improve and standardize the treatment of primary hypothyroidism in non-pregnant adults and to offer all the patients the best possible care across the Italian country. Target population: Non-pregnant adults with hypothyroidism. Excluded population: This GL does not cover the treatment of hypothyroidism in children and adolescents under 18 years of age, in women who are pregnant or breastfeeding, nor in subjects with central hypothyroidism. Also patients who require suppressive therapy with levothyroxine after thyroidectomy for thyroid cancer and those with transient iatrogenic hypothyroidism were not considered in this GL. Methods: The direct costs and the utilization of resources over time were evaluated for the implementation of the appropriate management within the National Health Service. Recommendations were based on the analysis, according to the GRADE methodology, of the evidence from literature. Patients preferences were collected and verified by means of specific bibliographic research and the active participation of two patients’ representatives in the GL development group. Results: The present GL provides 4 formal graded recommendations and 16 ungraded indications for good clinical practice. An elevated agreement was consistently obtained among the panel members. Conclusions: The present GL provides operative recommendations—based on the best available evidence and cost-effectiveness analysis—for the treatment of adult patients with primary hypothyroidism. The expected benefits from the dissemination, application and implementation of this GL are the improvement of the quality of care, its homogenization across the national territory and the rationalization of health expenditure in the respect of patient preferences.
- Open Access
- 15 January 2025
- Published by Aboutscience Srl in Global and Regional Health Technology Assessment
- Vol. 12 (1) , 186-193
Micro-costing analysis from Italian Guidelines for the management of sporadic primary hyperparathyroidism
Introduction: Primary hyperparathyroidism (PHPT) is a common endocrine disorder, primarily caused by singleadenomas or multiglandular disease. This study evaluates the economic impact of different PHPT treatment approaches from both the Italian National Health Service and societal perspectives.Methods: A micro-costing approach was used to estimate the costs of surgical and non-surgical treatments. Datawere gathered through a survey among panel members responsible for the Italian PHPT treatment guidelines,ensuring alignment with national clinical practice. The survey examined various cost components, including diagnostic tests, pre-hospitalization assessments, surgery duration, drug use, healthcare professionals involved,disposable materials, and follow-up care requirements.Results: The total cost for PHPT diagnosis and comorbidity assessment is € 887.96. Parathyroidectomy (PTX)costs € 4,588.00. Non-surgical alternatives, including pharmacological treatment (€ 953.34 annually) and activesurveillance (€ 197.42 annually), result in cumulative 30-year costs of € 28,590 and € 5,910, respectively. SincePTX is typically performed at age 55, pharmacological treatment over 30 years incurs an additional € 22,876 perpatient compared to surgery.Conclusions: Despite its higher upfront cost, PTX demonstrated long-term cost efficiency due to the relativelylow rates of follow-up complications and the absence of recurring annual costs associated with conservativestrategies.
- 15 January 2025
- Published by Aboutscience Srl in Global and Regional Health Technology Assessment
- Vol. 12 (1) , 186-193
Open AccessMicro-costing analysis from Italian Guidelines for the management of sporadic primary hyperparathyroidism
Introduction: Primary hyperparathyroidism (PHPT) is a common endocrine disorder, primarily caused by singleadenomas or multiglandular disease. This study evaluates the economic impact of different PHPT treatment approaches from both the Italian National Health Service and societal perspectives.Methods: A micro-costing approach was used to estimate the costs of surgical and non-surgical treatments. Datawere gathered through a survey among panel members responsible for the Italian PHPT treatment guidelines,ensuring alignment with national clinical practice. The survey examined various cost components, including diagnostic tests, pre-hospitalization assessments, surgery duration, drug use, healthcare professionals involved,disposable materials, and follow-up care requirements.Results: The total cost for PHPT diagnosis and comorbidity assessment is € 887.96. Parathyroidectomy (PTX)costs € 4,588.00. Non-surgical alternatives, including pharmacological treatment (€ 953.34 annually) and activesurveillance (€ 197.42 annually), result in cumulative 30-year costs of € 28,590 and € 5,910, respectively. SincePTX is typically performed at age 55, pharmacological treatment over 30 years incurs an additional € 22,876 perpatient compared to surgery.Conclusions: Despite its higher upfront cost, PTX demonstrated long-term cost efficiency due to the relativelylow rates of follow-up complications and the absence of recurring annual costs associated with conservativestrategies.
- 17 April 2024
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 47 (6) , 1361-1371
Italian guidelines for the management of adult individuals with overweight and obesity and metabolic comorbidities that are resistant to behavioral treatment
Aim This guideline (GL) is aimed at providing a clinical practice reference for the management of adult patients with overweight or obesity associated with metabolic complications who are resistant to lifestyle modification. Methods Surgeons, endocrinologists, gastroenterologists, psychologists, pharmacologists, a general practitioner, a nutritionist, a nurse and a patients’ representative acted as multi-disciplinary panel. This GL has been developed following the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. A systematic review and network meta-analysis was performed by a methodologic group. For each question, the panel identified potentially relevant outcomes, which were then rated for their impact on therapeutic choices. Only outcomes classified as “critical” and “important” were considered in the systematic review of evidence. Those classified as “critical” were considered for clinical practice recommendations. Consensus on the direction (for or against) and strength (strong or conditional) of recommendations was reached through a majority vote. Results The present GL provides recommendations about the role of both pharmacological and surgical treatment for the clinical management of the adult patient population with BMI > 27 kg/m2 and < 40 kg/m2 associated with weight-related metabolic comorbidities, resistant to lifestyle changes. The panel: suggests the timely implementation of therapeutic interventions in addition to diet and physical activity; recommends the use of semaglutide 2.4 mg/week and suggests liraglutide 3 mg/day in patients with obesity or overweight also affected by diabetes or pre-diabetes; recommends semaglutide 2.4 mg/week in patients with obesity or overweight also affected by non-alcoholic fatty liver disease; recommends semaglutide 2.4 mg/week as first-line drug in patients with obesity or overweight that require a larger weight loss to reduce comorbidities; suggests the use of orlistat in patients with obesity or overweight also affected by hypertriglyceridemia that assume high-calorie and high-fat diet; suggests the use of naltrexone/bupropion combination in patients with obesity or overweight, with emotional eating; recommends surgical intervention (sleeve gastrectomy, Roux-en-Y gastric bypass, or metabolic gastric bypass/gastric bypass with single anastomosis/gastric mini bypass in patients with BMI ≥ 35 kg/m2 who are suitable for metabolic surgery; and suggests gastric banding as a possible, though less effective, surgical alternative. Conclusion The present GL is directed to all physicians addressing people with obesity—working in hospitals, territorial services or private practice—and to general practitioners and patients. The recommendations should also consider the patient’s preferences and the available resources and expertise.
- 17 April 2024
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 47 (6) , 1361-1371
Italian guidelines for the management of adult individuals with overweight and obesity and metabolic comorbidities that are resistant to behavioral treatment
Aim This guideline (GL) is aimed at providing a clinical practice reference for the management of adult patients with overweight or obesity associated with metabolic complications who are resistant to lifestyle modification. Methods Surgeons, endocrinologists, gastroenterologists, psychologists, pharmacologists, a general practitioner, a nutritionist, a nurse and a patients’ representative acted as multi-disciplinary panel. This GL has been developed following the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. A systematic review and network meta-analysis was performed by a methodologic group. For each question, the panel identified potentially relevant outcomes, which were then rated for their impact on therapeutic choices. Only outcomes classified as “critical” and “important” were considered in the systematic review of evidence. Those classified as “critical” were considered for clinical practice recommendations. Consensus on the direction (for or against) and strength (strong or conditional) of recommendations was reached through a majority vote. Results The present GL provides recommendations about the role of both pharmacological and surgical treatment for the clinical management of the adult patient population with BMI > 27 kg/m2 and < 40 kg/m2 associated with weight-related metabolic comorbidities, resistant to lifestyle changes. The panel: suggests the timely implementation of therapeutic interventions in addition to diet and physical activity; recommends the use of semaglutide 2.4 mg/week and suggests liraglutide 3 mg/day in patients with obesity or overweight also affected by diabetes or pre-diabetes; recommends semaglutide 2.4 mg/week in patients with obesity or overweight also affected by non-alcoholic fatty liver disease; recommends semaglutide 2.4 mg/week as first-line drug in patients with obesity or overweight that require a larger weight loss to reduce comorbidities; suggests the use of orlistat in patients with obesity or overweight also affected by hypertriglyceridemia that assume high-calorie and high-fat diet; suggests the use of naltrexone/bupropion combination in patients with obesity or overweight, with emotional eating; recommends surgical intervention (sleeve gastrectomy, Roux-en-Y gastric bypass, or metabolic gastric bypass/gastric bypass with single anastomosis/gastric mini bypass in patients with BMI ≥ 35 kg/m2 who are suitable for metabolic surgery; and suggests gastric banding as a possible, though less effective, surgical alternative. Conclusion The present GL is directed to all physicians addressing people with obesity—working in hospitals, territorial services or private practice—and to general practitioners and patients. The recommendations should also consider the patient’s preferences and the available resources and expertise.
- Open Access
- 9 January 2024
- Published by Aboutscience Srl in Global and Regional Health Technology Assessment
- Vol. 11 (1) , 1-16
A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas
Background: Prolactinoma, the most common pituitary adenoma, is usually treated with dopamine agonist (DA) therapy like cabergoline. Surgery is second-line therapy, and radiotherapy is used if surgical treatment fails or in relapsing macroprolactinoma. Objective: This study aimed to provide economic evidence for the management of prolactinoma in Italy, using a cost-of-illness and cost-utility analysis that considered various treatment options, including cabergoline, bromocriptine, temozolomide, radiation therapy, and surgical strategies. Methods: The researchers conducted a systematic literature review for each research question on scientific databases and surveyed a panel of experts for each therapeutic procedure’s specific drivers that contributed to its total cost. Results: The average cost of the first year of treatment was €2,558.91 and €3,287.40 for subjects with microprolactinoma and macroprolactinoma, respectively. Follow-up costs from the second to the fifth year after initial treatment were €798.13 and €1,084.59 per year in both groups. Cabergoline had an adequate cost-utility profile, with an incremental cost-effectiveness ratio (ICER) of €3,201.15 compared to bromocriptine, based on a willingness-to-pay of €40,000 per quality-adjusted life year (QALY) in the reference economy. Endoscopic surgery was more cost-effective than cabergoline, with an ICER of €44,846.64. Considering a willingness-to-pay of €40,000/QALY, the baseline findings show cabergoline to have high cost utility and endoscopic surgery just a tad above that. Conclusions: Due to the favorable cost-utility profile and safety of surgical treatment, pituitary surgery should be considered more frequently as the initial therapeutic approach. This management choice could lead to better outcomes and an appropriate allocation of healthcare resources.
- 9 January 2024
- Published by Aboutscience Srl in Global and Regional Health Technology Assessment
- Vol. 11 (1) , 1-16
Open AccessA pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas
Background: Prolactinoma, the most common pituitary adenoma, is usually treated with dopamine agonist (DA) therapy like cabergoline. Surgery is second-line therapy, and radiotherapy is used if surgical treatment fails or in relapsing macroprolactinoma. Objective: This study aimed to provide economic evidence for the management of prolactinoma in Italy, using a cost-of-illness and cost-utility analysis that considered various treatment options, including cabergoline, bromocriptine, temozolomide, radiation therapy, and surgical strategies. Methods: The researchers conducted a systematic literature review for each research question on scientific databases and surveyed a panel of experts for each therapeutic procedure’s specific drivers that contributed to its total cost. Results: The average cost of the first year of treatment was €2,558.91 and €3,287.40 for subjects with microprolactinoma and macroprolactinoma, respectively. Follow-up costs from the second to the fifth year after initial treatment were €798.13 and €1,084.59 per year in both groups. Cabergoline had an adequate cost-utility profile, with an incremental cost-effectiveness ratio (ICER) of €3,201.15 compared to bromocriptine, based on a willingness-to-pay of €40,000 per quality-adjusted life year (QALY) in the reference economy. Endoscopic surgery was more cost-effective than cabergoline, with an ICER of €44,846.64. Considering a willingness-to-pay of €40,000/QALY, the baseline findings show cabergoline to have high cost utility and endoscopic surgery just a tad above that. Conclusions: Due to the favorable cost-utility profile and safety of surgical treatment, pituitary surgery should be considered more frequently as the initial therapeutic approach. This management choice could lead to better outcomes and an appropriate allocation of healthcare resources.
- Open Access
- 29 January 2016
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 48 (4) , 1581-1589
Placenta growth factor and neuropilin-1 collaborate in promoting melanoma aggressiveness
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications
- 29 January 2016
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 48 (4) , 1581-1589
Open AccessPlacenta growth factor and neuropilin-1 collaborate in promoting melanoma aggressiveness
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications
- 20 April 2015
- Published by S. Karger AG
- p. 231-233
The in vivo Effects of Insulin and Euglycemia on Mevalonate Concentrations in Humans
- 20 April 2015
- Published by S. Karger AG
- p. 231-233
The in vivo Effects of Insulin and Euglycemia on Mevalonate Concentrations in Humans
- Open Access
- 1 July 2014
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 142 (1) , 121-132
High Expression of the Mismatch Repair Protein MSH6 Is Associated With Poor Patient Survival in Melanoma
Objectives: The outcome of patients with primary melanoma (PM) cannot be completely explained based on currently adopted clinical-histopathologic criteria. In this study, we evaluated the potential prognostic value of mismatch repair protein expression in PMs.Methods: We examined the immunohistochemical staining of mismatch repair proteins in 18 benign nevi and 101 stage I to III PMs and investigated their association with tumor clinicopathologic variables and melanoma mortality.Results: Expression of MSH2, MLH1, and PMS2 was high in benign nevi and reduced in a subset of PMs. Conversely, MSH6 expression was absent or extremely low in benign nevi and increased in a subset of PMs. In the multivariate analysis, including sex, age, Breslow thickness, and ulceration, high MSH6 expression in PMs (ie, immunostaining in >20% of tumor cells) was significantly associated with an increased risk of melanoma mortality (relative risk, 3.76; 95% confidence interval, 1.12–12.70).Conclusions: MSH6 protein expression can be a valuable marker to improve prognosis assessment in PMs.
- 1 July 2014
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 142 (1) , 121-132
Open AccessHigh Expression of the Mismatch Repair Protein MSH6 Is Associated With Poor Patient Survival in Melanoma
Objectives: The outcome of patients with primary melanoma (PM) cannot be completely explained based on currently adopted clinical-histopathologic criteria. In this study, we evaluated the potential prognostic value of mismatch repair protein expression in PMs.Methods: We examined the immunohistochemical staining of mismatch repair proteins in 18 benign nevi and 101 stage I to III PMs and investigated their association with tumor clinicopathologic variables and melanoma mortality.Results: Expression of MSH2, MLH1, and PMS2 was high in benign nevi and reduced in a subset of PMs. Conversely, MSH6 expression was absent or extremely low in benign nevi and increased in a subset of PMs. In the multivariate analysis, including sex, age, Breslow thickness, and ulceration, high MSH6 expression in PMs (ie, immunostaining in >20% of tumor cells) was significantly associated with an increased risk of melanoma mortality (relative risk, 3.76; 95% confidence interval, 1.12–12.70).Conclusions: MSH6 protein expression can be a valuable marker to improve prognosis assessment in PMs.
- 1 January 1994
- Published by S. Karger AG in Annals of Nutrition and Metabolism
- Vol. 38 (5) , 257-262
The Effects of Insulin on Plasma Mevalonate Concentrations in Man
Mevalonate production is a limiting step in cholesterol synthesis. We studied the effects of insulin on plasma mevalonate concentrations during a 3-hour euglycemic hyperinsulinemic clamp study in 10 healthy males starting at 9 h a.m. after 14 h of fasting. Physiological variations in plasma mevalonate were evaluated on a different day from 9 to 12 h a.m. under saline infusion. During the clamp studies, slight but significant decreases were noted for VLDL-triglyceride and VLDL-cholesterol at 120 and 180 min (p < 0.05) and for apolipoprotein B-100 from 60min on (p < 0.05). Plasma mevalonate decreased significantly by 34 and 41% at 120 and 180 min, respectively (p < 0.001), while the mean percent decrease due to diurnal variations was 12% at 12 h a.m. In conclusion, hyperinsulinemia in the presence of euglycemia acutely decreases the circulating levels of mevalonic acid, the immediate product of HMG CoA reductase in the cholesterol pathway.
- 1 January 1994
- Published by S. Karger AG in Annals of Nutrition and Metabolism
- Vol. 38 (5) , 257-262
The Effects of Insulin on Plasma Mevalonate Concentrations in Man
Mevalonate production is a limiting step in cholesterol synthesis. We studied the effects of insulin on plasma mevalonate concentrations during a 3-hour euglycemic hyperinsulinemic clamp study in 10 healthy males starting at 9 h a.m. after 14 h of fasting. Physiological variations in plasma mevalonate were evaluated on a different day from 9 to 12 h a.m. under saline infusion. During the clamp studies, slight but significant decreases were noted for VLDL-triglyceride and VLDL-cholesterol at 120 and 180 min (p < 0.05) and for apolipoprotein B-100 from 60min on (p < 0.05). Plasma mevalonate decreased significantly by 34 and 41% at 120 and 180 min, respectively (p < 0.001), while the mean percent decrease due to diurnal variations was 12% at 12 h a.m. In conclusion, hyperinsulinemia in the presence of euglycemia acutely decreases the circulating levels of mevalonic acid, the immediate product of HMG CoA reductase in the cholesterol pathway.